meta
|
evidence
COVID-19
Living systematic review and meta-analysis
adjuvant therapies
anti-inflammatoty and immuno-therapy
antiandrogenic
antiviral and associated therapy
Amantadine
ASC09/ritonavir
azithromycin
azvudine
baloxavir marboxil
bromhexine
carrimycin
chloroquine and derivatives
chloroquine
hydroxychloroquine
zinc plus hydroxychloroquine
danoprevir / ritonavir
darunavir cobicistat
darunavir/cobicistat plus chloroquine
doxycycline
Emtricitabine/tenofovir plus colchicine plus rosuvastatin
Ensitrelvir (XOCOVA)
favipiravir
favipiravir plus interferon
fluvoxamine
hydroxychloroquine plus macrolides
azithromycin plus hydroxychloroquine
Interferon plus lopinavir/ritonavir
ivermectin
ivermectin plus doxycycline
leronlimab
lopinavir / ritonavir plus ribavirin
lopinavir/ritonavir
lopinavir/ritonavir plus chloroquine
Lopinavir/ritonavir plus hydroxychloroquine
lopinavir/ritonavir plus interferon ß-1a
lopinavir/ritonavir, ribavirin and interferon beta-1b
molnupiravir
niclosamide
nirmatrelvir / ritonavir (Paxlovid)
nitazoxanide
opaganib
oseltamivir
oseltamivir plus chloroquin
remdesivir
ribavirin
ritonavir
sofosbuvir
sofosbuvir and daclatasvir
sofosbuvir and ledipasvir
tenofovir/emtricitabine
tenofovir/emtricitabine plus hydroxychloroquine
tranexamic acid
tranilast
triazavirin
umifenovir (arbidol)
zinc
control
Drugs for acid related disorders
miscellaneous
Oral antidiabetic drugs
Renin-angiotensin-system-acting agents
vaccines
Vitamins
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
secondary prevention
Meta-analysis results for all treatments
Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
Treament
Trials
Summary
Endpoints
Emergency room visit or hospitalization
death D28
death or transfer to ICU
deaths
deaths (time to event analysis only)
hospitalization or death
A EFFACER PCR-negative (end of follow-up)
clinical deterioration
clinical improvement
clinical improvement (14-day)
clinical improvement (21-day)
clinical improvement (28-day)
clinical improvement (7-day)
clinical improvement (time to event analysis only)
confirmed COVID (any severity)
conversion to SARS-CoV- 2–positive status via NP swab
death or ventilation
hospital discharge
hospitalization
Influenza-like infection
mechanical ventilation
mechanical ventilation (time to event analysis only)
new illness compatible with Covid-19
radiologic improvement (14-day)
radiologic improvement (7-day)
Recovery (time to event analysis only)
symptomatic Covid-19
viral clearance
viral clearance (time to event analysis only)
viral clearance by day 14
viral clearance by day 7
asymptomatic COVID case
emergency room observation for > 6 hours or hospitalization
ICU admission
infection (PCR positive symptomatic or not)
off oxygenation
recovery
severe COVID-19 occurrence
AE leading to drug discontinuation
cardiac arrest
related AE (TRAE)
related SAE (TRSAE)
serious adverse events
superinfection
abnormal ECG findings
acute kidney injury
adverse events
arrhythmia
deep vein thrombosis
elevated liver enzymes
hyperbilirubinemia
long QT
pulmonary embolism
renal impairment
serious adverse events (SAE), any
severe adverse events
ventricular arrhythmia
Thromboembolic events
core analysis (OBS if no RCT)
RCTs only
all (RCT+OBS)
clinical deterioration
clinical improvement
deaths
viral clearance
chloroquine and derivatives
15
-
-
0.71
[0.25; 2.02], 3 RCTs, I2=0%
inconclusive result
-
ivermectin
4
-
-
0.71
[0.04; 11.32], 2 RCTs, I2=0%
inconclusive result
-
bromhexine
1
-
-
1.00
[0.02; 52.45], 1 RCT, I2=0%
inconclusive result
-
nirmatrelvir / ritonavir (Paxlovid)
1
-
-
-
-
Amantadine
0
-
-
-
-
ASC09/ritonavir
0
-
-
-
-
azithromycin
0
-
-
-
-
azvudine
0
-
-
-
-
baloxavir marboxil
0
-
-
-
-
carrimycin
0
-
-
-
-
danoprevir / ritonavir
0
-
-
-
-
darunavir cobicistat
0
-
-
-
-
doxycycline
0
-
-
-
-
Emtricitabine/tenofovir plus colchicine plus rosuvastatin
0
-
-
-
-
Ensitrelvir (XOCOVA)
0
-
-
-
-
favipiravir
0
-
-
-
-
favipiravir plus interferon
0
-
-
-
-
fluvoxamine
0
-
-
-
-
hydroxychloroquine plus macrolides
0
-
-
-
-
Interferon plus lopinavir/ritonavir
0
-
-
-
-
leronlimab
0
-
-
-
-
lopinavir / ritonavir plus ribavirin
0
-
-
-
-
lopinavir/ritonavir
0
-
-
-
-
lopinavir/ritonavir plus chloroquine
0
-
-
-
-
Lopinavir/ritonavir plus hydroxychloroquine
0
-
-
-
-
lopinavir/ritonavir plus interferon ß-1a
0
-
-
-
-
lopinavir/ritonavir, ribavirin and interferon beta-1b
0
-
-
-
-
molnupiravir
0
-
-
-
-
niclosamide
0
-
-
-
-
nitazoxanide
0
-
-
-
-
opaganib
0
-
-
-
-
oseltamivir
0
-
-
-
-
oseltamivir plus chloroquin
0
-
-
-
-
remdesivir
0
-
-
-
-
ribavirin
0
-
-
-
-
ritonavir
0
-
-
-
-
sofosbuvir
0
-
-
-
-
sofosbuvir and daclatasvir
0
-
-
-
-
sofosbuvir and ledipasvir
0
-
-
-
-
tenofovir/emtricitabine
0
-
-
-
-
tenofovir/emtricitabine plus hydroxychloroquine
0
-
-
-
-
tranexamic acid
0
-
-
-
-
tranilast
0
-
-
-
-
triazavirin
0
-
-
-
-
umifenovir (arbidol)
0
-
-
-
-
zinc
0
-
-
-
-